RxDoctor Payments Data

Elaine Phuah, DO

Internal Medicine · Fort Worth, TXNPI 1366719767

Payments from drug & device makers

$10,840in general payments, 2019–2025

Across 520 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Merz North America, Inc.$933
  • Abbott$865
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$772
  • Pfizer$559
  • Lilly USA, LLC$490
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,830100%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,840 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$84,098
Medicare patients
70
Services billed
2,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$41,071
TrulicityDulaglutide15$31,322
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$22,876
JardianceEmpagliflozin12$21,335
FarxigaDapagliflozin Propanediol11$18,693
VraylarCariprazine Hcl13$17,746
Repatha SureclickEvolocumab14$17,424
LinzessLinaclotide18$15,435
XareltoRivaroxaban12$8,982
Tresiba Flextouch U-200Insulin Degludec12$6,784
HorizantGabapentin Enacarbil12$6,080
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,993
Gabapentin31$911
Atorvastatin Calcium78$893
Oxycodone Hcl36$815

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$487$41,07129 claims
AbbVieVraylar, Linzess$3,150$33,18031 claims
Lilly USA, LLCTrulicity$490$31,32215 claims
GSKTrelegy Ellipta$123$22,87625 claims
Boehringer IngelheimJardiance$228$21,33512 claims
AstraZenecaFarxiga$318$18,69311 claims
Johnson & JohnsonXarelto$324$8,98212 claims
Arbor Pharmaceuticals, Inc.Horizant$105$6,08012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →